Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q4 2022 Results Conference Call February 22, 2023 11:30 AM ET
Company Participants
Wade Walke - SVP, IR
Brett Monia - CEO
Beth Hougen - CFO
Eugene Schneider - Chief Clinical Development Officer
Onaiza Cadoret - Chief Global Product Strategy & Operations Officer
Eric Swayze - EVP, Research
Conference Call Participants
Yanan Zhu - Wells Fargo Securities
Gary Nachman - BMO Capital Markets
Do Kim - Piper Sandler
Gena Wang - Barclays
Yale Jen - Laidlaw & Co.
Paul Matteis - Stifel
Jessica Fye - JP Morgan
Joseph Stringer - Needham & Company
Luca Issi - RBC
Mike Ulz - Morgan Stanley
Myles Minter - William Blair
Yaron Werber - Cowen
Operator
Good morning, and welcome to Ionis Pharmaceuticals Fourth Quarter and Full Year 2022 Financial Results Conference Call. [Operator Instructions]. As a reminder, this call is being recorded.
At this time, I would like to turn the call over to Wade Walke, Senior Vice President of Investor Relations, to lead off the call. Please begin, sir.
Wade Walke
Thank you, [Vishnari], Navin. Before we begin, I encourage everyone to go to the Investors section of the Ionis website to view the press release and related financial tables we will be discussing today, including a reconciliation of GAAP to non-GAAP financials. We believe non-GAAP financial results better represent the economics of our business and how we manage our business. We've also posted slides to our website that accompany today's call.
With me this morning are Brett Monia, our Chief Executive Officer; Eugene Schneider, Chief Clinical Development Officer; Onaiza Cadoret, Chief Global Product Strategy and Operations Officer; and Beth Hougen, our Chief Financial Officer; and Eric Swayze, our Executive Vice President of Research, will join us for the Q&A portion of the call.
I would like to
- Read more current IONS analysis and news
- View all earnings call transcripts